211 
Market Cap
Stock Chart
Halcygen - 30 Day Poll
Recent BLOGS About Halcygen Add New
Latest Company News
|
Mayne Pharma Group Limited Announces FDA Approval Of Dual-Scored 150MG Doryx Tablet
Reuters Key Development - Sep 14, 2011 |
|
Mayne Pharma Group Limited Announces No Final Dividend For FY 2011
Reuters Key Development - Aug 31, 2011 |
|
Mayne Pharma Group Limited Announces Change In Chief Financial Officer And Company Secretary
Reuters Key Development - Dec 20, 2010 |
|
Mayne Pharma Group Limited Announces Submission Of Marketing Authorisation Application For Subacap
Reuters Key Development - Dec 16, 2010 |
|
Halcygen Pharmaceuticals Limited Changes Name To Mayne Pharma Group Limited
Reuters Key Development - Nov 18, 2010 |
|
Halcygen Pharmaceuticals Limited Declares Maiden Dividend; Intends To Make Special Dividend
Reuters Key Development - Aug 31, 2010 |
Website
Videos related to Halcygen
Company Profile
HalcyGen Pharmaceuticals focuses on bringing reformulated existing drugs to the market, known as SuperGenerics.
The Company has two development programmes:
1. SUBA-itraconazole and Minocycline. SUBA-itraconazole is a bioavailable formulation of itraconazole, a synthetic broad-spectrum anti-fungal agent.
2. Minocycline is a member of the tetracycline antibiotic family. Minocycline is used to treat bacterial infections, including pneumonia and other respiratory tract infections, acne and infections of skin, genital, and urinary systems. It can also be used to eliminate bacteria from the nose and throat.
Key people:
The CEO, Dr Roger Aston , has international pharma/biotech experience:
Previously at Wellcome poc (now Glaxo Smith Kline), Dr Aston has more than 20 years of experience in the pharmaceutical and biotechnology industries. His previous positions have included CEO of Peptech Limited (Australia), Director of Cambridge Antibody Technology Limited (UK) and Chairman of Cambridge Drug Discovery Limited (UK - now BioFocus pic). Dr Aston was also founder and CEO of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr Aston was also a co-founder of pSivida Ltd.